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We previously reported that the ESR1 XbaI genotypes were 
associated with baseline and tamoxifen-induced serum 
lipid profiles. The analysis in that study was carried out 
by PCR followed by restriction-enzyme digestion. After 
reanalysis using more robust TaqMan assays, the findings 
related to ~10% of the genotypes for the ESR1 XbaI single-
nucleotide polymorphism (SNP) were revised. For the other 
genotypes (i.e., ESR1 PvuII, ESR2, and CYP2D6), the results 
were nearly identical to those in the previous study. Upon 
reanalysis, previously reported associations between the 
ESR1 Xba1 genotypes and baseline triglyceride and low-
density lipoprotein (LDL) cholesterol levels were no longer 
observed. Previously reported associations between the ESR1 
XbaI genotypes and tamoxifen-induced changes in levels of 
total cholesterol, triglycerides, and high-density lipoprotein 
(HDL) cholesterol were also no longer observed. However, 
the following observations from the original report did not 
change: (i) the levels of circulating lipids are lower in women 
taking tamoxifen; (ii) there is an association between the 
ESR2-02 genotypes and changes in triglyceride levels; and 
(iii) neither ESR1 PvuII nor CYP2D6 is associated with any 
changes in serum lipid concentrations in patients receiving 
treatment with tamoxifen.
Tamoxifen is a selective estrogen receptor modulator that has 
tissue-specific estrogen agonistic or antagonistic properties.1 
We and others have previously reported that tamoxifen induces 
favorable lipid profiles, presumably because of an estrogenic 
effect in the liver, mediated through the estrogen receptors α 
and β (ERα, β).2 The genes that encode these receptors (ESR1 
and 2) are highly polymorphic.3 Tamoxifen is a relatively  inactive 
prodrug, but it is converted to active metabolites, including 
4-hydroxy tamoxifen and 4-hydroxy-N-desmethyl tamoxifen 
(designated endoxifen).4 Conversion of tamoxifen to endoxifen 
is highly dependent on the activity of the enzymatic product 
of CYP2D6, which is also highly polymorphic.5 Therefore, we 
hypothesized that the estrogenic effects of tamoxifen on lipid 
profile might be associated with inherited single-nucleotide 
polymorphisms (SNPs) in the genes that encode for the targets 
or the metabolic enzymes that mediate its activity.
We previously reported2 that tamoxifen significantly lowered 
levels of low-density lipoprotein (LDL) cholesterol (P < 0.0001) 
and increased levels of triglycerides (P = 0.006). In postmenopausal 
women, the ESR1 XbaI GG genotype was associated with relatively 
greater tamoxifen-induced reductions in total cholesterol level as 
compared with the GA and AA genotypes (P = 0.03). The ESR1 
XbaI refers to the SNP rs no. 9340799, and the ESR1 PvuII refers 
to the SNP rs no. 2234693. In premenopausal women, the ESR1 
XbaI GG genotype was associated with a large tamoxifen-induced 
elevation in triglyceride concentration, whereas tamoxifen-treated 
women with the AA and AG genotypes had little or no change in 
triglyceride level (P = 0.002; gene–dose effect). In contrast, pre-
menopausal women with the ESR1 XbaI AA genotype showed 
elevated levels of high-density lipoprotein (HDL) cholesterol after 
4 months of treatment with tamoxifen, whereas those with the AG 
genotype showed no change in these levels, and those with the 
GG genotype showed a reduction (P = 0.004; gene–dose effect). In 
postmenopausal women, the ESR2-02 GG genotype was signifi-
cantly associated with tamoxifen-induced elevations in serum tri-
glyceride level, whereas there was no discernible change in women 
with the AG genotype and a reduction in triglyceride level in those 
with the AA genotype (P = 0.01; gene–dose effect). We concluded 
that estrogen receptor genotyping might be useful in predicting 
which patients would benefit more from tamoxifen.
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The genotyping data for ESR1 on which our prior report was 
based were generated by PCR followed by restriction-enzyme 
digestion (restriction fragment length polymorphism, RFLP), 
methods previously described by other investigators.6 We sub-
sequently redetermined the genotypes using TaqMan assays and 
found that ~10% of the genotypes for the ESR1 XbaI SNP, as 
determined by RFLP, were discordant. We report reanalysis of 
our data using the more accurate TaqMan assay.
Results
Comparison of genotype results obtained by taqMan assay 
vs. those obtained by RFlP
Each of the available 167 specimens was regenotyped using 
TaqMan methodology, for each of the genotypes (ESR1 XbaI 
and PvuII; ESR2-01 and -02) reported by Ntukidem et al.2 Each 
TaqMan genotype assay was performed on two separate occa-
sions. All replicate TaqMan assay results for each genotype were 
identical.
Concordance between the results of TaqMan and RFLP 
geno typing assays for ESR1 PvuII, ESR2-01, and -02 was ≥98%. 
TaqMan genotyping was successfully determined for ESR1 XbaI 
in 157 of the 167 available DNA specimens (see Supplementary 
Figure S1 online). Of these, 17 results (10.8%) showed discord-
ance on comparison.
Correlation between genotype and phenotype
Associations between esr1 PvuII, esr2, and Cyp2D6 genotypes, and 
lipid levels and clinical features. In the findings from the rean-
alysis, we observed that the previously reported associations 
between menopausal status and serum lipid concentrations at 
baseline, and between tamoxifen use and tamoxifen- associated 
change in lipid levels, remained unchanged. Likewise, as in 
the original report, changes in triglyceride levels were signifi-
cantly associated with ESR2-02 genotypes, whereas there was 
no association between either the ESR1 PvuII or the CYP2D6 
genotype and changes in serum lipid concentrations after 
tamoxifen treatment (see Supplementary Table S1 online and 
Supplementary Figure S1 online).
Associations between esr1 XbaI and lipids. We previously reported2 
a statistically significant association between total cholesterol 
level at baseline before tamoxifen treatment in all women and, 
in subgroup analysis, in premenopausal women with ESR1 
Xba1 genotypes. In the reanalysis with TaqMan assay genotyp-
ing, these associations were not observed (P = 0.23 and 0.94, 
respectively; Table 1). Likewise, previously reported associa-
tions were no longer detected between LDL-cholesterol level 
in the entire data set and in the premenopausal subgroup 
with ESR1 XbaI genotypes (P = 0.15 and 0.93, respectively; 
Table 1).
In agreement with the findings using RFLP genotyping, after 
4 months of treatment with tamoxifen, there were no detectable 
associations between TaqMan-analyzed ESR1 XbaI genotypes 
and levels of triglycerides, HDL cholesterol, and LDL cholesterol 
(Table 2). Although the previously reported association was 
again observed between the GG genotype of XbaI and greater 
reduction in total cholesterol level, it was not statistically sig-
nificant in the reanalysis (reduction in total cholesterol for each 
genotype: AA (n = 31) −28 mg/dl; AG (n = 30) −13 mg/dl; and 
GG (n = 13) −41 mg/dl; P = 0.06) (Table 2). Also, the previously 
reported correlations between XbaI genotypes and triglyceride 
levels in premenopausal women were not observed in the rea-
nalysis (Figure 1b). Although the changes in HDL-cholesterol 
levels associated with the XbaI genotypes were quantitatively 
similar to those previously observed in this group of patients, 
these changes failed to reach statistical significance in the rea-
nalysis (P = 0.09) (Figure 1c). As before, no statistically signifi-
cant associations were detected between XbaI genotypes and 
table 1 Mean baseline lipid concentrations according to eR-α Xbal genotype and menopausal status
er-α Xbal genotype lipid particle aa (n = 48) ag (n = 58) gg (n = 16) P valuea
All women (N = 122)b Total cholesterol 227 (213, 241)c 215 (204, 225) 234 (212, 256) 0.23
Triglycerides 141 (120, 161) 135 (106, 164) 131 (101, 160) 0.69
HDL cholesterol 61 (57, 65) 64 (60, 69) 64 (56, 72) 0.78
LDL cholesterol 137 (125, 149) 124 (115, 133) 144 (126, 162) 0.15
Premenopausal (n = 48) (N = 17) (N = 28) (N = 3)
Total cholesterol 211 (185, 238) 210 (193, 227) 208 (81, 335) 0.94
Triglycerides 141 (102, 180) 115 (67, 163) 92 (23, 161) 0.19
HDL cholesterol 59 (54, 65) 70 (63, 76) 68 (6, 130) 0.89
LDL cholesterol 123 (100, 146) 118 (106, 130) 122 (41, 202) 0.93
Postmenopausal (n = 74) (N = 31) (N = 30) (N = 13)
Total cholesterol 235 (218, 251) 220 (206, 233) 240 (217, 263) 0.30
Triglycerides 140 (115, 165) 153 (119, 187) 140 (106, 174) 0.72
HDL cholesterol 62 (56, 68) 60 (53, 67) 63 (55, 71) 0.58
LDL cholesterol 145 (131, 159) 129 (116, 143) 149 (129, 169) 0.29
HDL, high-density lipoprotein; LDL, low-density lipoprotein.
aP values are calculated for the differences between the AA/AG and GG alleles. bNumber of ER-α genotypes available. cMean baseline lipid particle concentration (95% CI).
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tamoxifen-induced changes in total cholesterol levels (P = 0.07) 
(Figure 1a) and LDL-cholesterol levels (P = 0.10) (Figure 1d).
DisCussion
Tamoxifen exerts its biological action through binding with its 
receptors, ERα and β, encoded by the genes ESR1 and 2, respec-
tively. Using an older assay, we had reported selected associa-
tions between SNPs in these genes and the favorable effect of 
tamoxifen on lipid profiles. In this report, we have identified that, 
for one of these alleles (ESR1 XbaI), reanalysis with the more 
accurate assay, TaqMan, indicated that ~10% of the  previously 
assigned genotypes were incorrect. In contrast, our previously 
reported genotypes for ESR1 PvuII, ESR2, and CYP2D6 were 
correct (98–100% concordance between assays).
In a reanalysis of the clinical associations of inherited germ-
line SNPs, using the genotypes derived from the TaqMan 
assays, we no longer detected the previously reported statisti-
cally  significant association between ESR1 Xba1 genotype and 
baseline triglyceride level in all women or between ESR1 Xba1 
genotype and baseline triglyceride or LDL-cholesterol level in 
the premenopausal subset. Likewise, in postmenopausal women, 
we no longer detected any statistically significant associations 
between ESR1 XbaI genotype and tamoxifen-induced changes 
in total cholesterol level, nor in premenopausal women between 
ESR1 XbaI genotype and tamoxifen-induced changes in triglyc-
eride or HDL-cholesterol level. Most of these differences in the 
findings are attributable to genotype reassignment in the ~10% 
of subjects in whom the genotype had initially been incorrectly 
assigned on the basis of RFLP genotyping.
These data may have relevance to many other studies using 
RFLP assays in general but specifically to those using it for 
detecting variants in ESR1, originally described by Herrington 
et al.6 We are not certain of the cause of the original genotyping 
errors. We believe that incomplete digestion of the PCR product 
by the XbaI enzyme may have contributed to the error, possibly 
because of a reagent problem, a tube heating block problem, or 
an unknown factor in the DNA sample that partially blocked 
the enzyme. Alternatively, there may have been some peak sup-
pression on the instrument that was used to analyze the digested 
PCR products. This circumstance could result from too little or 
too much DNA in the sample, a manufacturing problem with 
the chip, or an imperfection in the corresponding reagent. We 
table 2 Association between change in total cholesterol concentration at 4 months and eR-α Xbal genotypes in the postmenopausal 
group
er-α Xbal genotype
lipid particle aa (n = 31) ag (n = 30) gg (n = 13) P valuea
Total cholesterol −28 (−40, −16)b −13 (−22, −4) −41 (−62, −20) 0.06
Triglycerides 28 (4.5, 51) 29 (−33, 90) 27 (−37, 92) 0.98
HDL cholesterol −1 (−5.8, 3.6) 1.9 (−1.0, 4.8) −1.5 (−9.2, 6.1) 0.61
LDL cholesterol −32 (−43, −21) −16 (−25, −8) −39 (−60, −18) 0.17
HDL, high-density lipoprotein; LDL, low-density lipoprotein.
aP values are calculated for the differences between baseline and 4 months concentration for the AA/AG vs. the GG alleles. bChange in serum lipid particle concentration is shown 
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Figure 1 Response of serum lipid particle levels to tamoxifen in premenopausal women according to their ESR1 XbaI genotypes: (a) total cholesterol, 
(b) triglycerides, (c) high-density lipoprotein cholesterol, and (d) low-density lipoprotein cholesterol. The bars show the mean change in serum lipid 
concentration in mg/dl, and the error bars are the standard error of the means. The y axis indicates the direction of the change in lipid concentration. Shown 
in parentheses next to each genotype is the number of subjects in each genotype group. P value shown is for gene–dose effect.
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repeated the RFLP assay on the DNA samples from these sub-
jects and obtained the correct genotyping results, thereby indi-
cating that there is no problem specific to the SNP that affects the 
assay. Given that the frequencies of occurrence of these errors 
are small, they were not observed in our original development 
and validation of the RFLP assay. In summary, we believe that 
these are random errors that may or may not be present in assays 
conducted by other investigators.
It is possible that some of the differences in our  observations, 
such as the tamoxifen-induced changes in total cholesterol 
levels in postmenopausal women (P = 0.06; Table 2) and in 
HDL-cholesterol levels in premenopausal women (P = 0.09, 
Figure 1c), are attributable to loss of statistical power because 
not all the specimens were available for the reanalysis. However, 
power calculations for the results presented in Tables 1 and 2 
(current version), and their corresponding tables (Table 3a,b 
in the original version), do not support this hypothesis. It is 
clear that if the number of samples assayed were decreased, 
but the size of the genetic effects were assumed to be the same, 
then the 5% reduction in sample size would have led to only a 
3–4% reduction in power. Therefore, the difference between the 
original report and the reanalysis is unlikely to be due to the 
decrease in the number of samples per se. Instead, it appears 
that the loss of statistical power is the result of a decrease in 
the magnitude of the genetic effects observed, which in turn 
is a consequence of the reassignment of genotypes made 
necessary by the corrections in the genotyping results. The 
following other observations from the original submission 
have not changed: (i) circulating lipid levels are decreased 
in women taking tamoxifen, a finding that is consistent with 
other reports; (ii) changes in triglyceride levels were statisti-
cally associated with ESR2-02 genotype; and (iii) there was no 
association between either ESR1 PvuII or CYP2D6 genotype 
and changes in serum lipid concentrations after treatment with 
tamoxifen.
MethoDs
subjects, study design, sample collection, and lipid analysis. The sub-
jects, study design, sample collection, and lipid analysis details have 
been previously described, including exclusion of perimenopausal 
women and patients taking lipid-lowering medications (ClinicalTrials.
gov identifier NCT00228930) (ref. 2). Archived genomic DNA speci-
mens were selected for reanalysis using the TaqMan assay. Of the 176 
specimens included in the original report by Ntukidem et al., 9 had 
been exhausted by previous testing, and therefore 167 (95%) of the orig-
inal specimens were available for this reanalysis (see Supplementary 
Figure S1 online).
Genotyping. In our previous report,2 genotyping for ESR1 was conducted 
using the RFLP method, previously described in studies of the effects 
of estrogens on lipid levels in postmenopausal women,6 whereas ESR2 
genotyping was performed using the TaqMan method.2 In this study, 
to ensure uniform quality control, all specimens were regenotyped for 
ESR1 and ESR2 using TaqMan assays in accordance with the manufac-
turer’s instructions (Applied Biosystems, Foster City, CA) as previously 
described and validated7 (http://snp500cancer.nci.nih.gov; ESR2-01: rs 
no. 1256049; ESR2-02: rs no. 4986938). ESR1 genotypes for rs2234693 
(ESR1 PvuII) and rs9340799 (ESR1 XbaI) were determined using the 
following TaqMan assays: C_3163590_10 for the rs no. 2234693 and 
C_3163591_10 for the rs no. 9340799. In a previous publication by 
Consortium on Breast Cancer Pharmacogenomics (COBRA) investiga-
tors, the concordance rate between these two assays and manual DNA 
sequencing was >99% in 220 subjects.7 As a further confirmation, each 
specimen was genotyped twice using TaqMan assays, and any results that 
were discordant with the previous RFLP assay results were retested by 
DNA sequencing. All samples were also regenotyped for ESR2 using the 
TaqMan assay previously described.2 In our previous report, the results of 
the CYP2D6 genotyping were from at least two different methodologies 
that showed 100% concordance, and therefore we did not repeat CYP2D6 
genotyping in this genotyping analysis.
statistical analysis. Detailed methods for statistical analytical correla-
tions among clinical factors, lipids, and genotypes have been  previously 
described,2 and the reanalyses of these correlations in the current report 
were performed identically. In addition, a similar reanalysis was per-
formed by a completely separate and independent statistical team with 
identical results (see Supplementary Table S1 online, Supplementary 
Figure S1 online, and Acknowledgments).
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